Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02910583
Title Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

CLL/SLL

Therapies

Ibrutinib

Ibrutinib + Venetoclax

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.